Rex Ryan cries at this show of gamesmanship and the rout is on

And the Jets know the Pats haven’t forgotten that early beat down, and they’re likely still stinging from their shocking loss to the Colts.“We all know Belichick’s a known cheater,” says Mark Sanchez. “Who knew he was guilty of cheating himself And yet, he says he would do it again. Would that be called ‘4th-and-too’“Of course the Patriots don’t take too kindly to embarrassing defeat. When they’re out for revenge, they’re a lot like Oprah Winfrey they can drop 50 before you know it. We know we’ll have to play as well as, if not better than, we did in Week Two. Personally, I won’t rest easy until the game, and awiener, are in hand.”I predict that the Patriots come out fired up, and casually march 80 yards on their first possession for a score. Instead of kicking the extra point, Belichick again decides to "go for two," and this time succeeds, as Brady finds Ben Watson for the conversion.

Rex Ryan cries at this show of gamesmanship, and the rout is on. New England wins 37-20.. 8 /PRNewswire/ Quark Pharmaceuticals, Inc., adevelopment-stage pharmaceutical company discovering and developing novel RNAinterference (RNAi)-based therapeutics, today announced that it has initiatedpatient dosing in its Phase I/II clinical trial evaluating its systemicallyadministered siRNA drug candidate QPI-1002 (previously referred to as DGFi)for prevention of Delayed Graft Function (DGF) in patients undergoing deceaseddonor kidney transplantation. DGF represents Quark's second indication beingevaluated for the systemically administered dug candidate in human clinicaltrials. This trial follows two currently enrolling Phase I clinical trials inacute kidney injury (AKI).The multi-center, two-part Phase I/II clinical trial in DGF is expected toenroll up to 204 adult kidney transplant recipients. The first part of thestudy is a dose-escalation design to evaluate the safety and tolerability of asingle intravenous injection of QPI-1002 in renal transplant patients at highrisk to develop DGF. The second part of the study will evaluate safety andpotential clinical activity of a selected dose of QPI-1002 in the same patientpopulation.Patients will be enrolled in clinical sites in the United States.Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiationof patient dosing with QPI-1002 is an important milestone for Quark as well asbeing an innovative approach to offer therapeutic benefit to adult kidneytransplant patients at high risk for developing DGF. The siRNA drug candidateis based on the proprietary concept of Quark and reflects Quark's success indeveloping products originating from conceptually novel internal developments.These accomplishments further validate Quark's ability to advance innovativeproduct candidates from discovery into the clinic."Principal investigator Osama Gaber, M.D., F.A.C.S.

Director, Transplant Centerof Excellence at The Methodist Hospital, Houston, Texas said, "Our clinicalteam is excited to participate in clinical trials that evaluate new therapiesfor renal transplant patients. Patients that develop DGF following renaltransplantation have inferior kidney graft survival compared to those who donot. There is a real unmet medical need for a drug product to prevent DGF." Daniel Zurr, Chief Executive Officer, commented, "We are very pleased toannounce initiation of human dosing of the systemically administered QPI-1002in our Phase I/II trial in kidney transplant patients. These significant developments confirmthe robustness of Quark's clinical pipeline and the strength of itscapabilities in the RNAi arena."Delayed graft function (DGF) is one of the most common complications duringthe immediate postoperative period in renal transplantation and affects 25-40of the deceased donor renal transplants in the United States. DGF in renaltransplantation results most often from ischemia-reperfusion injury thatoccurs when the blood flow is re-established to the transplanted kidneyinitiating a chain of events that can lead to severe renal damage upontransplantation.